¼¼°èÀÇ ±â´É¼º ÀÚ±ÃÃâÇ÷ ½ÃÀå º¸°í¼­(2025³â)
Dysfunctional Uterine Bleeding Global Market Report 2025
»óǰÄÚµå : 1764306
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,272,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,065,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,859,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

±â´É¼º ÀÚ±ÃÃâÇ÷ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµÉ ¿¹Á¤ÀÔ´Ï´Ù. ÇコÄɾî ÀÎÇÁ¶óÀÇ È®´ë, ³·Àº ħ½À Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁý´Ï´Ù.

¿ù°æÀå¾ÖÀÇ À¯º´·ü »ó½ÂÀº ÇâÈÄ ¸î ³â°£ÀÇ ±â´É¼º ÀÚ±ÃÃâÇ÷ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­, Áø´Ü ¹æ¹ýÀÇ °³¼±¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ±â´É¼º ÀÚ±ÃÃâÇ÷Àº ±¸Á¶Àû ȤÀº Àü½ÅÀûÀÎ Áúȯ°ú´Â °ü·ÃÀÌ ¾ø´Â ºñÁ¤»óÀûÀÎ ÀÚ±ÃÃâÇ÷ ÆÐÅÏÀ» °ËÃâÇÏ´Â °ÍÀ¸·Î, ¿ù°æ Àå¾ÖÀÇ ÀÌÇØ¸¦ µ½°í, Á¤È®ÇÑ Áø´Ü°ú Ä¡·á¸¦ ¼­Æ÷Æ®ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 12¿ù ¿µ±¹¿¡ º»»ç¸¦ µÐ ºñ¿µ¸® ´ÜüÀÎ ·±´ø Æ®·¯½ºÆ®´Â ¿µ±¹¿¡¼­ 280¸¸ ¸íÀÌ »ý¸®¿ëǰÀ» ±¸ÀÔÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖÀ¸¸ç, ÀÌ´Â »ý¸®ÇÏ´Â »ç¶÷ 5¸í Áß 1¸í¿¡ ÇØ´çÇÏ´Â ¼öÄ¡·Î 2022³â 12%¿¡¼­ 2023³â 21%·Î Å©°Ô Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù.

±â´É¼º ÀÚ±ÃÃâÇ÷ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº °æ±¸ GnRH ±æÇ×Á¦¿Í °°Àº »õ·Î¿î Ä¡·á¹ýÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, È£¸£¸ó ¼öÁØÀ» Á¶Á¤ÇÏ¿© ¿ù°æ ´Ù·® ÃâÇ÷À» ¿ÏÈ­ÇÏ´Â È¿°úÀûÀÌ°í ºñ ¼ö¼úÀû ¼±ÅÃÀ» Á¦°øÇÕ´Ï´Ù. °æ±¸¿ë GnRH ±æÇ×Á¦´Â ¼º¼± ÀÚ±Ø È£¸£¸ó ¹æÃâ È£¸£¸ó ¼ö¿ëü¸¦ Â÷´ÜÇÏ°í ¿¡½ºÆ®·Î°Õ ¼öÄ¡¸¦ ³·Ã߸ç ħ½ÀÀû ½Ã¼ú ¾øÀÌ Àڱà ±ÙÁ¾À» Ãà¼ÒÇÏ´Â ¹æ½ÄÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 9¿ù ¿µ±¹ Á¦¾àȸ Theramex´Â Àڱà ±ÙÁ¾°ú °ü·ÃµÈ ¿ù°æ ´Ù·® ÃâÇ÷À» Ä¡·áÇϱâ À§ÇØ 1ÀÏ 1ȸ Åõ¿©µÈ °æ±¸ GnRH ±æÇ×Á¦ Yselty(Linzagorix)¸¦ Ãâ½ÃÇß½À´Ï´Ù. µû¶ó¼­ À¯¿¬ÇÑ Åõ¿©°¡ °¡´ÉÇÕ´Ï´Ù. ȯÀÚÀÇ QOLÀ» À¯ÁöÇϸ鼭 Áõ»óÀ» È¿°úÀûÀ¸·Î ¿ÏÈ­Çϰí Ä¡·á Áß Àӽżº ¿ÂÁ¸À» Áö¿øÇÕ´Ï´Ù.ÀüüÀûÀ¸·Î À̼¼¸£Æ¼´Â ÀڱñÙÁ¾°ú °ü·ÃµÈ ÃâÇ÷À» °ü¸®Çϱâ À§ÇÑ Çõ½ÅÀûÀÎ Àü·«ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Dysfunctional uterine bleeding (DUB) is characterized by abnormal uterine bleeding, typically caused by hormonal imbalances rather than structural issues. It primarily affects women of reproductive age and can manifest as heavy, prolonged, or irregular menstrual periods. DUB is diagnosed when no pelvic pathology, systemic illness, or pregnancy-related cause is identified. Treatment varies based on the severity and the patient's reproductive intentions.

The main categories of dysfunctional uterine bleeding are ovulatory and anovulatory. Ovulatory DUB occurs despite regular ovulation and often includes conditions like menorrhagia, polymenorrhagia, metrorrhagia, and dysmenorrhea. Diagnostic methods include hysteroscopy, ultrasonography, dilation and curettage, and endometrial biopsy. These techniques are used in managing menopause, dysfunctional uterine bleeding, endometrial cancer, contraception, hyperplastic precursor lesions, and other conditions. The primary end users include hospitals, clinics, diagnostic centers, and pharmaceutical companies.

The dysfunctional uterine bleeding market research report is one of a series of new reports from The Business Research Company that provides dysfunctional uterine bleeding market statistics, including the dysfunctional uterine bleeding industry global market size, regional shares, competitors with the dysfunctional uterine bleeding market share, detailed dysfunctional uterine bleeding market segments, market trends, and opportunities, and any further data you may need to thrive in the dysfunctional uterine bleeding industry. This dysfunctional uterine bleeding market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dysfunctional uterine bleeding market size has grown strongly in recent years. It will grow from $3.29 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be credited to the rising prevalence of hormonal imbalances, growing awareness of menstrual health, increased adoption of hormone therapy treatments, a higher number of women seeking gynecological care, and expanding research and development in women's health.

The dysfunctional uterine bleeding market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth projected for the forecast period is driven by the increasing prevalence of menstrual disorders, heightened awareness of women's health, greater adoption of advanced diagnostic techniques, expanding healthcare infrastructure, and a growing demand for minimally invasive treatments. Key trends during this period include progress in non-hormonal treatment options, improvements in diagnostic tools for menstrual disorders, development of minimally invasive surgical methods, innovations in menstrual health tracking technologies, and enhanced patient awareness and education initiatives.

The rising prevalence of menstrual disorders is expected to drive the growth of the dysfunctional uterine bleeding market in the coming years. Menstrual disorders encompass any irregularities or abnormalities in the menstrual cycle, such as changes in the frequency, duration, or volume of bleeding. This increase in menstrual disorders is fueled by greater awareness, lifestyle changes, and improved diagnostic methods that allow more cases to be identified and treated. Dysfunctional uterine bleeding aids in understanding menstrual disorders by detecting abnormal uterine bleeding patterns that are not linked to structural or systemic diseases, thereby supporting accurate diagnosis and treatment. For example, in December 2023, the Trust for London, a UK-based nonprofit, reported that 2.8 million people in the UK struggled to afford period products-equivalent to one in five menstruating individuals-and a significant rise from 12% in 2022 to 21% in 2023. Thus, the growing prevalence of menstrual disorders is contributing to the expansion of the dysfunctional uterine bleeding market.

Leading companies in the dysfunctional uterine bleeding market are concentrating on developing new treatments, such as oral GnRH antagonists, to offer effective, non-surgical options that reduce heavy menstrual bleeding by regulating hormone levels. An oral GnRH antagonist works by blocking gonadotropin-releasing hormone receptors, lowering estrogen levels, and shrinking uterine fibroids without the need for invasive procedures. For example, in September 2024, Theramex, a UK-based pharmaceutical firm, launched Yselty (linzagolix), an oral, once-daily GnRH antagonist aimed at treating heavy menstrual bleeding associated with uterine fibroids. This medication offers flexible dosing to better customize treatment for individual patients. It effectively alleviates symptoms while preserving patients' quality of life and supports fertility preservation during treatment. Overall, Yselty represents an innovative strategy for managing bleeding related to uterine fibroids.

In January 2025, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. This acquisition adds the Sonata System to Hologic's portfolio-an innovative, incision-free treatment for uterine fibroids linked to heavy menstrual bleeding. The technology offers uterus-preserving options, strengthening Hologic's position in the abnormal uterine bleeding market. Gynesonics Inc., also based in the US, specializes in non-surgical medical devices that treat conditions causing dysfunctional uterine bleeding (DUB).

Major players in the dysfunctional uterine bleeding market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Medtronic plc, Boston Scientific Corporation, Smith & Nephew plc, Sun Pharmaceutical Industries Ltd., Hologic Inc., Sumitomo Pharma, Karl Storz SE & Co. KG, Cook Medical Incorporated, Gedeon Richter Plc, Lupin Ltd., Torrent Pharmaceuticals Ltd., CooperSurgical Inc., Ferring Pharmaceuticals SA, Minerva Surgical Inc., and Medgyn Products Inc.

North America was the largest region in the dysfunctional uterine bleeding market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysfunctional uterine bleeding report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dysfunctional uterine bleeding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dysfunctional uterine bleeding market includes revenues earned by entities by providing services such as emergency care services, fertility and reproductive health services, and telemedicine and virtual care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dysfunctional Uterine Bleeding Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dysfunctional uterine bleeding market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for dysfunctional uterine bleeding ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dysfunctional uterine bleeding market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Dysfunctional Uterine Bleeding Market Characteristics

3. Dysfunctional Uterine Bleeding Market Trends And Strategies

4. Dysfunctional Uterine Bleeding Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Dysfunctional Uterine Bleeding Growth Analysis And Strategic Analysis Framework

6. Dysfunctional Uterine Bleeding Market Segmentation

7. Dysfunctional Uterine Bleeding Market Regional And Country Analysis

8. Asia-Pacific Dysfunctional Uterine Bleeding Market

9. China Dysfunctional Uterine Bleeding Market

10. India Dysfunctional Uterine Bleeding Market

11. Japan Dysfunctional Uterine Bleeding Market

12. Australia Dysfunctional Uterine Bleeding Market

13. Indonesia Dysfunctional Uterine Bleeding Market

14. South Korea Dysfunctional Uterine Bleeding Market

15. Western Europe Dysfunctional Uterine Bleeding Market

16. UK Dysfunctional Uterine Bleeding Market

17. Germany Dysfunctional Uterine Bleeding Market

18. France Dysfunctional Uterine Bleeding Market

19. Italy Dysfunctional Uterine Bleeding Market

20. Spain Dysfunctional Uterine Bleeding Market

21. Eastern Europe Dysfunctional Uterine Bleeding Market

22. Russia Dysfunctional Uterine Bleeding Market

23. North America Dysfunctional Uterine Bleeding Market

24. USA Dysfunctional Uterine Bleeding Market

25. Canada Dysfunctional Uterine Bleeding Market

26. South America Dysfunctional Uterine Bleeding Market

27. Brazil Dysfunctional Uterine Bleeding Market

28. Middle East Dysfunctional Uterine Bleeding Market

29. Africa Dysfunctional Uterine Bleeding Market

30. Dysfunctional Uterine Bleeding Market Competitive Landscape And Company Profiles

31. Dysfunctional Uterine Bleeding Market Other Major And Innovative Companies

32. Global Dysfunctional Uterine Bleeding Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dysfunctional Uterine Bleeding Market

34. Recent Developments In The Dysfunctional Uterine Bleeding Market

35. Dysfunctional Uterine Bleeding Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â